Literature DB >> 29184684

Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery.

Gilbert Z Murimwa1, Puja S Venkat2, William Jin1, Susan Leuthold2, Kujtim Latifi2, Khaldoun Almhanna3, Jose M Pimiento3, Jacques-Pierre Fontaine3, Sarah E Hoffe2, Jessica M Frakes2.   

Abstract

BACKGROUND: Sarcopenia is an independent predictor of clinical outcomes in multiple gastrointestinal cancers. Total psoas area (TPA), as measured on a single cross-sectional CT image at the L4 vertebral body level, has been correlated with sarcopenia. We sought to evaluate whether TPA was predictive of acute grade ≥3 toxicity, pathologic response, and overall survival in patients with locally advanced esophageal cancer receiving tri-modality therapy.
METHODS: An institutional database of esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery was queried. Of 77 patients treated from 2008 to 2012 with intensity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT), 56 patients were eligible based on having CT imaging that included the L4 vertebral body. The L4 vertebra was identified on axial CT and the psoas muscle was manually contoured bilaterally to determine the skeletal muscle index. Sarcopenia was defined by the presence of the psoas area less than the median of the cohort. Acute toxicity was defined as within 3 months of radiotherapy based on Common Terminology Criteria for Adverse Events. ROC curve, logistic regression, and Kaplan Meier estimates were used when appropriate.
RESULTS: Sarcopenia was associated with increased acute grade ≥3 toxicity from chemoradiation by ROC analysis using a cut off of 841.5 mm2/m2 (P=0.003, AUC 0.709, sensitivity 60.9%, specificity 78.8%) and logistic regression (P=0.002). Patients with TPA <841.5 mm2/m2 were 5.78 times more likely to develop grade 3 or higher toxicity (P=0.004). Sarcopenia did not predict a difference in overall survival (P=0.217) and was not significant for pathologic complete response or favorable pathologic response (TRG 0/1).
CONCLUSIONS: In our cohort of patients, sarcopenia was associated with a significant increase in acute grade ≥3 toxicity with chemoradiation, suggesting a potential role for neoadjuvant patient selection strategies. There was no difference in pathologic response or overall survival.

Entities:  

Keywords:  Radiotherapy; esophageal neoplasms; neoadjuvant therapy; sarcopenia; total psoas area (TPA)

Year:  2017        PMID: 29184684      PMCID: PMC5674260          DOI: 10.21037/jgo.2017.06.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  22 in total

1.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

2.  Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography.

Authors:  N Mitsiopoulos; R N Baumgartner; S B Heymsfield; W Lyons; D Gallagher; R Ross
Journal:  J Appl Physiol (1985)       Date:  1998-07

3.  Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer.

Authors:  Yuji Miyamoto; Yoshifumi Baba; Yasuo Sakamoto; Mayuko Ohuchi; Ryuma Tokunaga; Junji Kurashige; Yukiharu Hiyoshi; Shiro Iwagami; Naoya Yoshida; Megumi Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2015-01-07       Impact factor: 5.344

4.  Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.

Authors:  Sami Antoun; Laura Birdsell; Michael B Sawyer; Peter Venner; Bernard Escudier; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

5.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Authors:  Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

6.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

7.  Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

Authors:  Daniel A Galvão; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

Authors:  Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 9.  Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism.

Authors:  Charles T Lutz; LeBris S Quinn
Journal:  Aging (Albany NY)       Date:  2012-08       Impact factor: 5.682

10.  Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.

Authors:  Younak Choi; Do-Youn Oh; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

View more
  11 in total

1.  Morphomic Factors Associated With Complete Response to Neoadjuvant Therapy in Esophageal Carcinoma.

Authors:  Chien-Hung Chiu; Peng Zhang; Andrew C Chang; Brian A Derstine; Brian E Ross; Binu Enchakalody; Nidhi V Shah; Stewart C Wang; Yin-Kai Chao; Jules Lin
Journal:  Ann Thorac Surg       Date:  2019-09-21       Impact factor: 4.330

2.  Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.

Authors:  Naoki Kamitani; Kazuhiro Migita; Sohei Matsumoto; Kohei Wakatsuki; Tomohiro Kunishige; Hiroshi Nakade; Shintaro Miyao; Masayuki Sho
Journal:  Surg Today       Date:  2019-07-15       Impact factor: 2.549

3.  Actual Sarcopenia Reflects Poor Prognosis in Patients with Esophageal Cancer.

Authors:  Akihiro Watanabe; Taro Oshikiri; Ryuichiro Sawada; Hitoshi Harada; Naoki Urakawa; Hironobu Goto; Hiroshi Hasegawa; Shingo Kanaji; Kimihiro Yamashita; Takeru Matsuda; Daisuke Makiura; Yoshihiro Kakeji
Journal:  Ann Surg Oncol       Date:  2022-02-15       Impact factor: 5.344

4.  Association of adipose tissue and skeletal muscle metrics with overall survival and postoperative complications in soft tissue sarcoma patients: an opportunistic study using computed tomography.

Authors:  Robert D Boutin; Jeremy R Katz; Abhijit J Chaudhari; Jonathan G Yabes; Jonah S Hirschbein; Yves-Paul Nakache; J Anthony Seibert; Ramit Lamba; Ghaneh Fananapazir; Robert J Canter; Leon Lenchik
Journal:  Quant Imaging Med Surg       Date:  2020-08

Review 5.  Impact and Treatment of Sarcopenia in Patients Undergoing Radiotherapy: A Multidisciplinary, AMSTAR-2 Compliant Review of Systematic Reviews and Metanalyses.

Authors:  Federica Medici; Alberto Bazzocchi; Milly Buwenge; Alice Zamagni; Gabriella Macchia; Francesco Deodato; Savino Cilla; Pierandrea De Iaco; Anna Myriam Perrone; Lidia Strigari; Stefania Rizzo; Alessio G Morganti
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

6.  Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with 18F-FDG PET/CT muscle metrics.

Authors:  Cathy Zhou; Brent Foster; Rosalie Hagge; Cameron Foster; Leon Lenchik; Abhijit J Chaudhari; Robert D Boutin
Journal:  Ann Nucl Med       Date:  2019-12-10       Impact factor: 2.668

7.  Deep Convolutional Neural Network-Based Positron Emission Tomography Analysis Predicts Esophageal Cancer Outcome.

Authors:  Cheng-Kun Yang; Joe Chao-Yuan Yeh; Wei-Hsiang Yu; Ling-I Chien; Ko-Han Lin; Wen-Sheng Huang; Po-Kuei Hsu
Journal:  J Clin Med       Date:  2019-06-13       Impact factor: 4.241

8.  Sarcopenia in cancer: Risking more than muscle loss.

Authors:  Milan Anjanappa; Michael Corden; Andrew Green; Darren Roberts; Peter Hoskin; Alan McWilliam; Ananya Choudhury
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-11-09

9.  A Single Axial Slice of the Sternocleidomastoids and Paravertebral Muscles Associated with Worse Local Progression-Free Survival and Severe Toxicity in Sarcopenic Head and Neck Cancer Patients Undergoing Radiotherapy.

Authors:  William Jin; Benjamin Rich; Raphael Yechieli; Laura Freedman; Michael A Samuels; Matthew Abramowitz; Ruben Carmona; Stuart E Samuels
Journal:  Cureus       Date:  2022-02-21

10.  Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer.

Authors:  Han Gyul Yoon; Dongryul Oh; Yong Chan Ahn; Jae Myoung Noh; Hongryull Pyo; Won Kyung Cho; Yun Mi Song; Minsu Park; Na Young Hwang; Jong-Mu Sun; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.